Team:Freiburg/Highlights

From 2013.igem.org

(Difference between revisions)
Line 29: Line 29:
     <li>...design a <b>catalytically inactive version of Cas9</b> and designing a new class of DNA binding proteins.</li>
     <li>...design a <b>catalytically inactive version of Cas9</b> and designing a new class of DNA binding proteins.</li>
-
     <li>...combine this modified Cas9 with <b>different effectors</b>.</li>
+
     <li>...combine this modified dCas9 with <b>different effectors</b>.</li>
     <li>...express the system in various <b>mammalian cell lines</b>.</li>
     <li>...express the system in various <b>mammalian cell lines</b>.</li>
     <li>...control human <b>gene expression</b> via our modified CRISPR/Cas system.</li>
     <li>...control human <b>gene expression</b> via our modified CRISPR/Cas system.</li>
Line 41: Line 41:
</p>
</p>
<p>
<p>
-
A mutated Cas9 derived protein without nickase function was our start. This is basically a DNA binding protein, that is relying on a <b>protein-RNA-DNA </b>  
+
A mutated Cas9 derived protein without nickase function was our start. This is basically a DNA binding protein, that is relying on a <b>protein-RNA-DNA</b>  
-
 
+
interaction.
interaction.
  </p><p></p><p>
  </p><p></p><p>
-
By fusing <b>effector domains</b> to Cas9 we altered the properties in various ways.</p>
+
By fusing <b>effector domains</b> to dCas9 we altered the properties in various ways.</p>
<p id="h3">Activation
<p id="h3">Activation
Line 60: Line 59:
<tr>
<tr>
<td> <b>Figure 1: Activation by Cas9:VP16 </b><br>
<td> <b>Figure 1: Activation by Cas9:VP16 </b><br>
-
By fusing the transcriptional activation domain VP16 to Cas9, we are able to activate a SEAP reporter transcription.
+
By fusing the transcriptional activation domain VP16 to dCas9, we are able to activate a SEAP reporter transcription.
</td>
</td>
</tr>
</tr>
Line 66: Line 65:
</div>
</div>
-
<p id="h3">Repression
+
<p id="h3"> Repression
</p>
</p>
Line 77: Line 76:
</tr>
</tr>
<tr>
<tr>
-
<td> <b>Figure 2: Repression via Cas9:KRAB </b><br>
+
<td> <b>Figure 2: Repression via dCas9:KRAB </b><br>
-
Using Cas9:KRAB we were able to repress GFP expression in mammalian cells.
+
Using dCas9:KRAB we were able to repress GFP expression in mammalian cells.
</td>
</td>
</tr>
</tr>
Line 98: Line 97:
</tr>
</tr>
<tr>
<tr>
-
<td> <b>Figure 3: Endogenous, stable repression by Cas9:G9a </b><br>
+
<td> <b>Figure 3: Endogenous, stable repression by dCas9:G9a </b><br>
-
Chromatin remodeling, resulting in repression of endogenous genes is possible by fusing the histone methyltransferase G9a to Cas9.
+
Chromatin remodeling, resulting in repression of endogenous genes is possible by fusing the histone methyltransferase G9a to dCas9.
</td>
</td>
</tr>
</tr>
Line 125: Line 124:
We developed an ELISA based method. With this method we can quantify the <b>binding efficiency </b>of our proteins. We called this binding assay <b>uniBAss</b>. It is  
We developed an ELISA based method. With this method we can quantify the <b>binding efficiency </b>of our proteins. We called this binding assay <b>uniBAss</b>. It is  
-
a powerful tool for the characterization of the interaction between the modified Cas9 and the locus specific RNA.
+
a powerful tool for the characterization of the interaction between the modified dCas9 and the locus specific RNA.
</p> <p>
</p> <p>
<div>
<div>

Revision as of 20:53, 29 September 2013


Highlights

In the last months we were able to...

  • ...design a catalytically inactive version of Cas9 and designing a new class of DNA binding proteins.
  • ...combine this modified dCas9 with different effectors.
  • ...express the system in various mammalian cell lines.
  • ...control human gene expression via our modified CRISPR/Cas system.
  • ...control gene expression on light stimulus.
  • ...standardize dCas9 by mutating illegal iGEM restriction sites.

Our toolkit ...

A mutated Cas9 derived protein without nickase function was our start. This is basically a DNA binding protein, that is relying on a protein-RNA-DNA interaction.

By fusing effector domains to dCas9 we altered the properties in various ways.

Activation

The activation domain VP16 is able to activate transcription of genes.

Figure 1: Activation by Cas9:VP16
By fusing the transcriptional activation domain VP16 to dCas9, we are able to activate a SEAP reporter transcription.

Repression

The fusion of the transcriptional repressor domain KRAB leads to synthetic repression of gene expression.

Figure 2: Repression via dCas9:KRAB
Using dCas9:KRAB we were able to repress GFP expression in mammalian cells.

Chromatin modification (Repression)

Specific chromatin modification was achieved by fusing a histone methyltransferase G9a to dCas9. With this protein we are able to specifically repress endogenous gene expression.

Figure 3: Endogenous, stable repression by dCas9:G9a
Chromatin remodeling, resulting in repression of endogenous genes is possible by fusing the histone methyltransferase G9a to dCas9.

Light switch

We were able to induce our system on light stimulus. This was possible by using photorecetors of higher plants.

Targeting with RNAimer

By building a plasmid containing the necessary RNAs and insertion sites for targeting we created a modular, BioBrick compatible system for multiple DNA targeting: The RNAimer. Using our RNAimer plasmid it is easy to combine several target sequences on one plasmid using the BioBrick standard.

uniBAss - Binding Assay

We developed an ELISA based method. With this method we can quantify the binding efficiency of our proteins. We called this binding assay uniBAss. It is a powerful tool for the characterization of the interaction between the modified dCas9 and the locus specific RNA.

Figure 4: uniBAss
We developed an assay for testing the binding capacity of our constructs.

Conclusion

In summary, we established a new modularized toolkit for modulating gene expression: The uniCAS Toolkit!

Retrieved from "http://2013.igem.org/Team:Freiburg/Highlights"